RAD51C vs RAD51D: Inherited-Risk Evidence in Context
RAD51C and RAD51D are RAD51 paralogs involved in homologous recombination. Pathogenic germline variants are associated with inherited cancer predisposition, but risk is modified by family history and should be interpreted through genetics care.
Quick Answer
RAD51C and RAD51D are RAD51 paralogs involved in homologous recombination. Pathogenic germline variants are associated with inherited cancer predisposition, but risk is modified by family history and should be interpreted through genetics care.
Related but Not Identical
Both genes encode repair factors, but each has its own evidence base and variant classifications. A gene-panel result should retain the precise gene and the laboratory's classification.
Risk Is Personal
Published risk estimates are population summaries. Family history, ancestry and other modifiers can change an individual's risk discussion, which is why genetics-led counselling is appropriate.
Key Takeaways
- ·RAD51C and RAD51D are homologous-recombination genes.
- ·Pathogenic germline findings merit specialist interpretation.
- ·A VUS does not establish inherited risk.
Put these genes in pathway context
Frequently asked questions
What is the key idea in RAD51C vs RAD51D: Inherited-Risk Evidence in Context?
RAD51C and RAD51D are RAD51 paralogs involved in homologous recombination. Pathogenic germline variants are associated with inherited cancer predisposition, but risk is modified by family history and should be interpreted through genetics care.
What should be kept with the result or mechanism?
RAD51C and RAD51D are homologous-recombination genes. Pathogenic germline findings merit specialist interpretation. A VUS does not establish inherited risk.
References
Continue Reading
BRCA1 and Ovarian Cancer Risk: How to Read a Result
3 min read
BRCA1 vs BRCA2: Different Roles in DNA Repair
2 min read
PALB2: DNA Repair, Inherited Risk and Tumour Findings
2 min read
Homologous Recombination Deficiency: BRCA, ATM and HRD Testing
6 min read
BRIP1 and Cancer Risk: What the Evidence Supports
3 min read
Variant of Uncertain Significance: How to Read a VUS Result
2 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
BRCA1 has 100+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.